Relmada Therapeutics (RLMD) Amortization of Deferred Charges (2014 - 2017)
Relmada Therapeutics (RLMD) posted quarterly Amortization of Deferred Charges of $2819.0 for Q3 2017, down 96.42% quarter-over-quarter from $78724.0 in Q2 2014.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Amortization of Deferred Charges (2014 - 2017) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Amortization of Deferred Charges for 2 consecutive years, with $2819.0 the latest figure, recorded in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 2,819.00 |
| Jun 30, 2014 | 78,724.00 |
| Mar 31, 2014 | 65,760.00 |